Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders
Hennique Knobbe1, Elvera A. Damer2, Mireille A. Edens3, Bas S.W.A. Nij Bijvank4, Marieke A.C. Hemels5, Peter G.J. ter Horst1, 6
1: Isala, Department of Clinical Pharmacy, E=hennique@hotmail.com ; 2: Isala, Department of Psychiatry, E=e.a.damer@isala.nl; 3: Isala, Isala Academie, E=m.a.edens@isala.nl ; 4: Isala, Department of Gynecology and Obstetrics, E= s.w.a.nijbijvank@isala.nl ; 5: Isala, Department of Neonatology, E=m.a.c.hemels@isala.nl ; 6: Corresponding author: Dr. P.G.J. ter Horst, Ph.D., PharmD, hospital pharmacist. Isala; department of Clinical Pharmacy; dr van Heesweg 2; 8025 AB Zwolle, The Netherlands; T= 0031 38 424 2469; E=p.g.j.ter.horst@isala.nl